What's Happening?
Scribe Therapeutics has been awarded over $25 million by the California Institute for Regenerative Medicine (CIRM) to advance its CRISPR-based gene editing therapies for cardiometabolic diseases. The funding supports the development of STX-1200 and STX-1400,
targeting lipoprotein(a) and triglycerides, respectively. These therapies aim to provide durable, single-dose treatments for conditions like atherosclerotic cardiovascular disease and severe hypertriglyceridemia.
Why It's Important?
The funding from CIRM represents a significant investment in the potential of CRISPR technology to address prevalent health issues. Cardiovascular disease is a leading cause of death, and innovative treatments like those being developed by Scribe Therapeutics could revolutionize patient care. By targeting genetic causes of disease, these therapies offer the promise of more effective and long-lasting solutions, potentially reducing healthcare costs and improving patient outcomes.
